DE69915143D1 - Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen - Google Patents

Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen

Info

Publication number
DE69915143D1
DE69915143D1 DE69915143T DE69915143T DE69915143D1 DE 69915143 D1 DE69915143 D1 DE 69915143D1 DE 69915143 T DE69915143 T DE 69915143T DE 69915143 T DE69915143 T DE 69915143T DE 69915143 D1 DE69915143 D1 DE 69915143D1
Authority
DE
Germany
Prior art keywords
nhr
heteroaryl
aryl
age
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69915143T
Other languages
English (en)
Other versions
DE69915143T2 (de
Inventor
Alangudi Sankaranarayanan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE69915143D1 publication Critical patent/DE69915143D1/de
Publication of DE69915143T2 publication Critical patent/DE69915143T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Hydrogenated Pyridines (AREA)
DE69915143T 1999-10-06 1999-10-15 Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen Expired - Lifetime DE69915143T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN828CA1999 1999-10-06
INCA082899 1999-10-06
PCT/IB1999/001683 WO2001025208A1 (en) 1999-10-06 1999-10-15 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
DE69915143D1 true DE69915143D1 (de) 2004-04-01
DE69915143T2 DE69915143T2 (de) 2004-10-14

Family

ID=11084928

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69915143T Expired - Lifetime DE69915143T2 (de) 1999-10-06 1999-10-15 Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen

Country Status (19)

Country Link
US (2) US6462057B1 (de)
EP (1) EP1222171B1 (de)
JP (1) JP4068843B2 (de)
CN (1) CN100355731C (de)
AT (1) ATE260256T1 (de)
AU (1) AU769940B2 (de)
BR (1) BRPI9913746F8 (de)
CA (1) CA2344144C (de)
CZ (1) CZ291789B6 (de)
DE (1) DE69915143T2 (de)
DK (1) DK1222171T3 (de)
ES (1) ES2216644T3 (de)
HK (1) HK1044335B (de)
HU (1) HU227523B1 (de)
MX (1) MXPA02003495A (de)
PL (1) PL211112B1 (de)
PT (1) PT1222171E (de)
RU (1) RU2215000C2 (de)
WO (1) WO2001025208A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103228A1 (en) * 1999-10-06 2002-08-01 Torrent Pharmaceuticals Ltd. Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
CN100355731C (zh) * 1999-10-06 2007-12-19 托伦脱药品有限公司 吡啶衍生物及其用途
JP2004525904A (ja) * 2000-12-29 2004-08-26 アルテオン インコーポレイテッド 線維性疾患又は他の適応症ｉｉｉｃの治療方法
CZ303214B6 (cs) * 2001-03-21 2012-05-30 Torrent Pharmaceuticals Ltd Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití
PT1243581E (pt) * 2001-03-21 2005-11-30 Torrent Pharmaceuticals Ltd Compostos de piridinio uteis no tratamento de doencas relacionadas com age
CN1259316C (zh) 2001-04-05 2006-06-14 托伦脱药品有限公司 用于老龄相关性和糖尿病性血管***并发症的杂环类化合物
US20050043408A1 (en) * 2001-10-15 2005-02-24 Faustinus Yeboah Anti-glycation agents for preventing age- diabetes- and smoking-related complications
HUP0104831A2 (hu) * 2001-10-19 2003-08-28 Torrent Pharmaceuticals Ltd. Készítmény és eljárás piridíniumszármazékok gyógyászati alkalmazására
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
RU2010135524A (ru) * 2008-01-25 2012-02-27 Торрент Фармасьютикалз Лтд. (In) Фармацевтические комбинации
US20120058105A1 (en) 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
KR20120018185A (ko) 2009-05-07 2012-02-29 토렌트 파마슈티칼스 리미티드 당뇨병 치료에 유용한 피페리딘 유도체
AU2016246124B2 (en) * 2015-04-08 2019-11-14 Torrent Pharmaceuticals Limited Pharmaceutical formulations
MX2017012943A (es) * 2015-04-08 2018-01-30 Torrent Pharmaceuticals Ltd Nuevos compuestos de piridinio.
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5272176A (en) 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5137916A (en) 1985-11-14 1992-08-11 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
JPH05216151A (ja) * 1992-02-06 1993-08-27 Konica Corp ハロゲン化銀写真感光材料
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
JP4067562B2 (ja) * 1995-01-18 2008-03-26 アルテオン インコーポレイテッド 進行性グリコシル化最終生成物の生成を阻止し、反転するためのチアゾリウム化合物の使用
CN100355731C (zh) * 1999-10-06 2007-12-19 托伦脱药品有限公司 吡啶衍生物及其用途

Also Published As

Publication number Publication date
HUP0104116A2 (hu) 2002-03-28
PL348327A1 (en) 2002-05-20
BR9913746A (pt) 2002-04-23
ES2216644T3 (es) 2004-10-16
AU5994299A (en) 2001-05-10
CN1318056A (zh) 2001-10-17
ATE260256T1 (de) 2004-03-15
US6624178B2 (en) 2003-09-23
DE69915143T2 (de) 2004-10-14
BR9913746F1 (pt) 2020-07-07
CN100355731C (zh) 2007-12-19
AU769940B2 (en) 2004-02-12
PT1222171E (pt) 2004-07-30
CZ291789B6 (cs) 2003-05-14
CA2344144C (en) 2008-12-02
BR9913746E8 (pt) 2018-05-02
JP2003511369A (ja) 2003-03-25
BR9913746F8 (pt) 2021-11-30
HK1044335A1 (en) 2002-10-18
BR9913746C1 (pt) 2002-08-13
JP4068843B2 (ja) 2008-03-26
BRPI9913746B8 (pt) 2021-05-25
HK1044335B (zh) 2004-09-10
HU227523B1 (en) 2011-07-28
EP1222171B1 (de) 2004-02-25
PL211112B1 (pl) 2012-04-30
CZ20011033A3 (cs) 2001-08-15
HUP0104116A3 (en) 2002-04-29
US20030092744A1 (en) 2003-05-15
BR9913746B1 (pt) 2013-03-19
RU2215000C2 (ru) 2003-10-27
CA2344144A1 (en) 2001-04-12
MXPA02003495A (es) 2004-04-05
US6462057B1 (en) 2002-10-08
EP1222171A1 (de) 2002-07-17
DK1222171T3 (da) 2004-07-05
BRPI9913746F8 (pt) 2022-01-18
WO2001025208A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
DE69915143D1 (de) Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen
KR100638684B1 (ko) 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
DE3784905T2 (de) Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten.
US10751353B2 (en) Compositions and methods for treating an aggregation disease or disorder
EP1941880B1 (de) Ein pyridoncarbonsäure-derivat enthaltende lotion
CA2011063C (en) Nicardipine pharmaceutical composition for parenteral administration
EP0781554A1 (de) Hydroxylradikalfänger
ATE6645T1 (de) Dibenzoxazepin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JP2024091930A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP3253302B2 (ja) ３−ジアルキルアミノエトキシベンゾイル−ベンゾフランを含有する非経口溶液
BR9915962A (pt) Composto da série do piridìnio, processos para a preparação de composto da série do piridìnio e de uma formulação parenteral, uso de um composto, composição farmacêutica para tratar complicações diabéticas e doenças associadas ao envelhecimento, e, método para tratar um paciente diabético e para prevenir ou tratar doenças causadas por complicações associadas à diabetes e ao envelhecimento
EP1727545B1 (de) Verwendung von n-piperidin-derivaten zur behandlung von neurodegenerativen erkrankungen
EP0667157A1 (de) Mittel zur behandlung von kreislaufbeschwerden
AU2005216862A1 (en) Compositions comprising prodrugs of proton pump inhibitors
EP2228365A1 (de) Pharmazeutische Kombination aus 5-Fluorouracil und neuen wasserlöslichen 2,6-Dimethyl-1,4-Dihydropyridin-3,5-Dicarbonsäureesterähnlichen Verbindungen
US20070112041A1 (en) Nicardipine injection composition
EP2801348A1 (de) Orale waschzusammensetzung zur vorbeugung und/oder behandlung von periodontopathien
WO1990015603A1 (fr) Composition antipruritique
DE3855824T2 (de) Anti-Plasmin Depressant
US20220288096A1 (en) Compositions and methods for treating an aggregation disease or disorder
ES2322538T3 (es) Inhibidores contra el aumento de la tension ocular causada por irradiacion con laseres, que contienen derivados de 1,4-dihidropiridina.
JP4490536B2 (ja) 脳血管障害に基づく疾患の予防又は治療薬
JP2002363076A (ja) フマギロール誘導体を用いる腫瘍の治療方法
CH666183A5 (it) Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
HUP0105469A2 (hu) Pirroloazepineket tartalmazó gyógyászati készítmények claudicatio intermittens kezelésére

Legal Events

Date Code Title Description
8364 No opposition during term of opposition